Ibutamoren
In the stimulating scenario of GH production, the long-term safety of treatment with growth hormone (GH) is an area of ​​much debate. Healthy elderly people who took the MK-677 mimetic experienced a sustained increase in the amplitude of pulsatile GH and IGF-I secretion to the levels seen in young adults [38].
GH reduces abdominal visceral fat (GVA) in GH deficient and obese adults, postmenopausal women, but not in normal elderly people. Despite the increased GH levels, MK-677 did not affect GAV, perhaps because its combined orexigenic and adipogenic effects neutralized the lipolytic effects of the GH increase. Finally, although MK-677 did not reduce GVA, it did reduce LDL levels in 12 months and the unobserved effect on GH in normal elderly people [38].
In a randomized clinical trial, ibutamoren for 12 months was well tolerated and increased GH secretion and fat-free mass, but not muscle strength in healthy elderly people. However, development was halted because ibutamoren was associated with the risk of heart failure in a randomized study to examine safety and efficacy in patients with hip fractures [38].